Biotech company 7TM Pharma, based north of Copenhagen has put a second anti-obesity compound, codename TM30339, into phase I/II clinical development. The company's lead molecule TM30338, is currently moving towards phase II clinical studies.
Obesity and related metabolic disorders are considered a major health problem and a growing challenge to the developed world. According to the World Health Organization there are more than 400 million clinically obese people in the world, yet current obesity treatments are few in number and reportedly have limited efficacy. The commercial value of any successful new anti-obesity drug would naturally be astronomical.
TM30339 works in a similar way to the body's natural satiety hormone, called pancreatic polypeptide. The drug mimics the "full stomach" signal sent to the brain from the gastrointestinal tract when sufficient food intake has occurred.
Thue Schwartz, research director of 7TM Pharma says: "It is very important for us to put a further compound into testing. Both candidate drugs are first-in-class, and both function on the satiety mechanism which we know is a very effective way to achieve weight loss." The news was reported by national daily newspaper Jyllands-Posten.
7TM Pharma is a discovery and development biopharmaceutical company which focuses on new drugs targeting 7TM receptors. It is estimated that approximately 40% of today’s prescription drugs target 7TM receptors, but utilize only 5% of the known 7TM receptor targets.
Current investors in 7TM Pharma include Novo A/S, Index Ventures, Johnson & Johnson Development Corporation, the venture capital subsidiary of Johnson & Johnson
The core therapeutic focus of 7TM Pharma is metabolic disorders, including obesity. The company has entered into several collaborative partnerships, including agreements with Ortho-McNeil, Inc., a Johnson & Johnson subsidiary.